Gearhardt AN, Boswell RG, White MA The association of "food addiction" with disordered eating and body mass index. Eat Behav. 2014 Aug;15(3):427-33. doi: 10.1016/j.eatbeh.2014.05.001. Epub 2014 May 27.
Gearhardt AN, Corbin WR, Brownell KD Development of the Yale Food Addiction Scale Version 2.0. Psychol Addict Behav. 2016 Feb;30(1):113-21. doi: 10.1037/adb0000136.
Gupta A, Osadchiy V, Mayer EA Brain-gut-microbiome interactions in obesity and food addiction. Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):655-672. doi: 10.1038/s41575-020-0341-5. Epub 2020 Aug 27.
Kalon E, Hong JY, Tobin C, Schulte T Psychological and Neurobiological Correlates of Food Addiction. Int Rev Neurobiol. 2016;129:85-110. doi: 10.1016/bs.irn.2016.06.003. Epub 2016 Jul 22.
Koob GF, Volkow ND Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016 Aug;3(8):760-773. doi: 10.1016/S2215-0366(16)00104-8.
Ramirez V, Wiers CE, Wang GJ, Volkow ND Personality traits in substance use disorders and obesity when compared to healthy controls. Addiction. 2020 Nov;115(11):2130-2139. doi: 10.1111/add.15062. Epub 2020 Apr 29.
Volkow ND, Wang GJ, Tomasi D, Baler RD The addictive dimensionality of obesity. Biol Psychiatry. 2013 May 1;73(9):811-8. doi: 10.1016/j.biopsych.2012.12.020. Epub 2013 Jan 29.
Volkow ND, Wise RA How can drug addiction help us understand obesity? Nat Neurosci. 2005 May;8(5):555-60. doi: 10.1038/nn1452. No abstract available.
Williams MR, Stedtfeld RD, Tiedje JM, Hashsham SA MicroRNAs-Based Inter-Domain Communication between the Host and Members of the Gut Microbiome. Front Microbiol. 2017 Sep 27;8:1896. doi: 10.3389/fmicb.2017.01896. eCollection 2017.
Involvement of the Gut Microbiota-brain Cross-talk in the Loss of Eating Control (GMBCrossTalkFood)
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.